Tumor Biomarkers: Clinical Utility, Promises and Problems

ISSN: 2213-4778 (Online)
ISSN: 2213-476X (Print)


Volume 1, 3 Issues, 2014


Download PDF Flyer




Applied Clinical Research, Clinical Trials and Regulatory Affairs

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Satish Chandra
Tawam Hospital
Al Ain
UAE


View Full Editorial Board

Subscribe Order Reprints


Tumor Biomarkers: Clinical Utility, Promises and Problems

Author(s): Saeeda Almarzooqi

Affiliation: Pathology Department, College of Medicine & Health Sciences, UAE University, Al Ain, UAE.

Abstract

The word biomarker has different meanings to different physicians. A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” by the National Institutes of Health Biomarkers Definitions Working Group held in 1998. Thus, the definition of a biomarker may include routinely measured parameters in clinical practice such as blood pressure and pulse or it could indicate a substances used in the diagnosis, treatment and monitoring of a disease. Here, we discuss tumor biomarkers as an example of commonly used clinical biomarkers that impact patient diagnosis and prognosis. In addition, a review of the limitations of common biomarkers and a highlight of emerging and promising biomarkers are presented in the manuscript.

Keywords: Tumor, biomarkers, prognosis, predictive, validation, breast cancer, lung cancer, EGFR, intra-tumoral heterogeneity, resistance.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 1
Issue Number: 1
First Page: 51
Last Page: 55
Page Count: 5
DOI: 10.2174/2213476X01666131121224127
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science